A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB VERSUS DOCETAXEL FOR ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER IN SECOND LINE IN A HEALTHCARE SETTING